➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,431,597

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,431,597 protect, and when does it expire?

Patent 8,431,597 protects DAURISMO and is included in one NDA.

This patent has fifty-one patent family members in forty-three countries.

Summary for Patent: 8,431,597
Title:Benzimidazole derivatives
Abstract: The present invention relates to a compound of the Formula I ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3A, R.sup.3B, R.sup.4, R.sup.5, X, m, and n are as defined herein. Such novel benzamidazole derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
Inventor(s): Munchhof; Michael J. (Salem, CT), Reiter; Lawrence A. (Mystic, CT), La Greca; Susan D. (Old Lyme, CT), Jones; Christopher S. (Gales Ferry, CT), Li; Qifang (Stonington, CT)
Assignee: Pfizer Inc. (New York, NY)
Application Number:13/404,169
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,431,597

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pfizer DAURISMO glasdegib maleate TABLET;ORAL 210656-001 Nov 21, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Pfizer DAURISMO glasdegib maleate TABLET;ORAL 210656-002 Nov 21, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,431,597

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 2377   Start Trial
Argentina 067346   Start Trial
Argentina 103632   Start Trial
Australia 2008272641   Start Trial
Brazil PI0813412   Start Trial
Canada 2690953   Start Trial
Chile 2008001922   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.